Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2019-10-24 Interim / Quarterly Rep…
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon Q3 2019 reults
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Biotec Pharmacon ASA for Q3 2019. It contains detailed financial statements (Consolidated Statement of Profit & Loss), operational reviews, management commentary on business trends, and financial position analysis. It is not an earnings release (which would be a short summary) nor an announcement of a report (RPA), as it provides the full substantive financial data and analysis for the period. Q3 2019
2019-10-24 English
Biotec Pharmacon Q3 2019 reults
Earnings Release Classification · 100% confidence The document explicitly states it announces the 'third quarter and first nine months 2019 results' and provides key financial highlights (sales, gross profit, EBITDA, cash-flow) for Q3 2019. This content structure—a brief announcement summarizing key figures for a specific fiscal period shorter than a year—is characteristic of an Earnings Release (ER). It is not the comprehensive report itself (which would be an IR), nor is it a transcript (CT) or a management discussion (MDA). Given the short length (2414 chars) and focus on immediate results highlights, ER is the most appropriate classification. Q3 2019
2019-10-24 English
Biotec Pharmacon ASA appoints Dr. Jethro Holter as interim CEO
Board/Management Information Classification · 100% confidence The document is a press release announcing a change in senior management: the appointment of Dr. Jethro Holter as interim CEO, succeeding Christian Jorgensen. This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is short (2400 chars) and is a direct announcement, not a detailed report or a notice about a report's publication.
2019-10-23 English
Biotec Pharmacon ASA appoints Dr. Jethro Holter as interim CEO
Board/Management Information Classification · 100% confidence The document explicitly announces the appointment of Dr. Jethro Holter as the interim Chief Executive Officer (CEO) of Biotec Pharmacon ASA, succeeding the current CEO. This action directly relates to changes in the company's senior management team. This aligns perfectly with the definition for Board/Management Information (MANG). The document is short and focused solely on this personnel change.
2019-10-23 English
Biotec Pharmacon ASA: Invitation to presentation of Q3 2019 results
Report Publication Announcement Classification · 95% confidence The document is very short (873 characters) and serves as an invitation and announcement for the presentation of the Q3 2019 results. It explicitly states when and where the presentation will occur and mentions that the 'report for the third quarter 2019 will be available' at a specific time. This structure—announcing an upcoming event and the availability of a related report—strongly suggests this is an announcement about the release/presentation, rather than the full Interim Report (IR) or Earnings Release (ER) itself. Since it is announcing the presentation and the availability of the results report, the most fitting category is Report Publication Announcement (RPA), as it is announcing the publication/presentation of the results.
2019-10-16 English
Biotec Pharmacon ASA: Invitation to presentation of Q3 2019 results
Report Publication Announcement Classification · 98% confidence The document is titled 'Biotec Pharmacon ASA: Invitation to presentation of Q3 2019 results' and explicitly states that the company will present its Q3 2019 results on a specific date (October 24, 2019). It provides details about the presentation time, venue, and webcast link. Crucially, it mentions that the Q3 2019 report will be available on newsweb.no and the company homepage from 07:00 a.m. on that date. Since the document is very short (970 chars) and serves primarily to announce *when* and *where* the results presentation and the report itself will be released, it fits the definition of a Report Publication Announcement (RPA) rather than the full Earnings Release (ER) or Interim Report (IR).
2019-10-16 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.